Adalimumab damps flares among patients in remission
Patients with active, non-radiographic axial spondyloarthritis who achieve remission on adalimumab have fewer flares if they continue taking it compared with those ceasing the medication, a study shows.
The ABILITY-3 trial, conducted in 20 countries and funded by AbbVie, enrolled adult patients with evidence of active inflammation, active disease, and inadequate response to at least two non-steroidal anti-inflammatory drugs.
During the 28-week lead-in period, all 673 participants received 40mg subcutaneous adalimumab every other week. The 305 patients who achieved an Ankylosing